Drugs for Albuminuria
Start with an ACE inhibitor or ARB at the highest tolerated dose, then add an SGLT2 inhibitor, and finally consider adding a non-steroidal mineralocorticoid receptor antagonist (finerenone) if albuminuria remains elevated despite dual therapy.
First-Line Therapy: RAS Inhibition
Begin with either an ACE inhibitor or ARB (not both) as foundational therapy. For adults with CKD and severely increased albuminuria (A3), RAS inhibitors are strongly recommended regardless of diabetes status 1. For moderately increased albuminuria (A2), RAS inhibitors are recommended with diabetes and suggested without diabetes 1, 2.
Critical implementation points:
- Titrate to the highest approved dose that is tolerated—the proven benefits were achieved at these doses 1, 2
- Monitor serum creatinine and potassium within 2-4 weeks of initiation or dose increase 1, 2
- Continue therapy unless creatinine rises >30% within 4 weeks 1, 2
- Continue even when eGFR falls below 30 mL/min/1.73 m² 1
Managing hyperkalemia: Use potassium-lowering strategies (dietary restriction, diuretics, potassium binders) rather than immediately reducing or stopping the RAS inhibitor 1, 2.
Second-Line: Add SGLT2 Inhibitor
For patients with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m², add an SGLT2 inhibitor on top of RAS blockade 1. This combination is the only intervention proven to reduce both mortality (OR 0.81) and end-stage kidney disease (OR 0.69) 3. Once started, continue even if eGFR falls below 20 mL/min/1.73 m² unless not tolerated 1.
The SGLT2 inhibitor provides complementary renoprotection through tubuloglomerular feedback restoration and afferent arteriole constriction, working synergistically with RAS blockade 4.
Third-Line: Consider Non-Steroidal MRA
If albuminuria remains ≥30 mg/g despite RAS inhibitor plus SGLT2 inhibitor, and serum potassium is normal, add finerenone 2. This triple therapy achieves the most dramatic albuminuria reduction—96% of patients achieved >50% reduction versus 50% with SGLT2 inhibitor alone 5.
Key evidence:
- Combination of SGLT2 inhibitor plus non-steroidal MRA reduces albuminuria by approximately 33% more than SGLT2 inhibitor alone 6
- Finerenone reduces albuminuria even without concurrent RAS inhibitor, though the effect is more pronounced with co-administration 7
- The combination does not significantly increase hyperkalemia risk compared to SGLT2 inhibitor monotherapy in real-world practice 5
Alternative: Steroidal MRA (Spironolactone)
If finerenone is unavailable or unaffordable, low-dose spironolactone (12.5 mg daily) effectively reduces albuminuria when added to RAS blockade 8. At this dose, hyperkalemia risk is manageable, though potassium monitoring remains essential 9.
Spironolactone-specific warnings 9:
- Monitor potassium within 1 week of initiation and regularly thereafter
- Risk of gynecomastia (9% in males, dose-dependent)
- Contraindicated in pregnancy
- Can cause hypotension and worsening renal function with excessive diuresis
Critical Monitoring Algorithm
Within 2-4 weeks of starting or increasing any agent:
- Check serum creatinine: Accept up to 30% increase; if >30%, evaluate for acute kidney injury, volume depletion, or renal artery stenosis 2
- Check potassium: If elevated, review concurrent medications (NSAIDs, potassium supplements), moderate dietary potassium, correct volume depletion before reducing doses 2
- Check blood pressure: Reduce dose only if symptomatic hypotension occurs 1
Common Pitfalls to Avoid
- Never combine ACE inhibitor + ARB + direct renin inhibitor—this triple RAS blockade is contraindicated 1
- Do not discontinue potassium supplementation abruptly without checking levels in heart failure patients starting spironolactone 9
- Do not stop RAS inhibitors prematurely for modest creatinine rises or asymptomatic hyperkalemia—use management strategies first 1, 2
- Do not delay SGLT2 inhibitor addition in diabetic patients—the mortality and kidney benefits are substantial 3